Skip to main content
Back
ELAN logo

Elanco Animal Health Incorporated

Data quality: 100%
ELAN
NYSE Healthcare Drug Manufacturers - Specialty & Generic
$24.92
▲ $0.48 (1.96%)
Mkt Cap: 12.39B
Day Range
$24.01 $25.41
52-Week Range
$8.02 $27.72
Volume
6,816,204
50D / 200D Avg
$24.58 / $20.18
Prev Close
$24.44

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (627 peers)

Metric Stock Sector Median
P/E -53.4 0.4
P/B 1.9 2.9
ROE % -3.7 3.7
Net Margin % -4.9 3.9
Rev Growth 5Y % -0.3 10.0
D/E 0.6 0.2

Analyst Price Target

Hold
$27.88 +11.9%
Low: $22.00 High: $30.00
Forward P/E
23.7
Forward EPS
$1.03
EPS Growth (est.)
+0.0%
Est. Revenue
5 B

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $1.53
$1.50 – $1.54
6 B 2
FY2029 $1.44
$1.42 – $1.45
5.8 B 4
FY2028 $1.33
$0.36 – $2.38
5.5 B 6

Key Takeaways

Revenue declined -0.26% annually over 5 years
Earnings declined -168.64% over the past year
Generating 284.00M in free cash flow
PEG of 0.29 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 6.48%
Capital efficient — spends only 5.85% of revenue on capex

Growth

Revenue Growth (5Y)
-0.26%
Revenue (1Y)6.22%
Earnings (1Y)-168.64%
FCF Growth (3Y)55.80%

Quality

Return on Equity
-3.67%
ROIC1.79%
Net Margin-4.92%
Op. Margin5.34%

Safety

Debt / Equity
0.61
Current Ratio2.17
Interest Coverage1.15

Valuation

P/E Ratio
-53.40
P/B Ratio1.89
EV/EBITDA62.94
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 6.22% Revenue Growth (3Y) 3.32%
Earnings Growth (1Y) -168.64% Earnings Growth (3Y) N/A
Revenue Growth (5Y) -0.26% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 4.72B Net Income (TTM) -232.00M
ROE -3.67% ROA -1.74%
Gross Margin 43.48% Operating Margin 5.34%
Net Margin -4.92% Free Cash Flow (TTM) 284.00M
ROIC 1.79% FCF Growth (3Y) 55.80%
Safety
Debt / Equity 0.61 Current Ratio 2.17
Interest Coverage 1.15 Dividend Yield 0.00%
Valuation
P/E Ratio -53.40 P/B Ratio 1.89
P/S Ratio 2.63 PEG Ratio 0.29
EV/EBITDA 62.94 Dividend Yield 0.00%
Market Cap 12.39B Enterprise Value 15.86B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 4.72B 4.44B 4.42B 4.41B 4.76B
Net Income -232.00M 338.00M -1.23B -78.00M -483.00M
EPS (Diluted) -0.47 0.68 -2.50 -0.15 -0.97
Gross Profit 2.05B 1.91B 1.94B 1.97B 2.08B
Operating Income 252.00M 251.00M 326.00M 384.00M 304.00M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 13.36B 12.61B 14.36B 15.49B 16.48B
Total Liabilities 6.81B 6.52B 8.14B 8.20B 8.97B
Shareholders' Equity 6.55B 6.10B 6.22B 7.29B 7.51B
Total Debt 4.02B 4.32B 5.77B 5.84B 6.32B
Cash & Equivalents 545.00M 468.00M 352.00M 345.00M 638.00M
Current Assets 3.46B 3.22B 3.41B 3.28B 3.27B
Current Liabilities 1.60B 1.32B 1.24B 1.70B 1.65B